LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.

    Kulanthaivel, Shanmugaraj / Kaliberdenko, Vitalii B / Balasundaram, Keerthanaa / Shterenshis, Michael V / Scarpellini, Emidio / Abenavoli, Ludovico

    Reviews on recent clinical trials

    2020  Volume 16, Issue 2, Page(s) 138–145

    Abstract: Introduction: Corona virus is a group of viruses that cause diseases in mammals and birds. In humans, these families of viruses can cause respiratory infections from a mild form to fatal. It is preferably called coronavirus. Formally, it is known as ... ...

    Abstract Introduction: Corona virus is a group of viruses that cause diseases in mammals and birds. In humans, these families of viruses can cause respiratory infections from a mild form to fatal. It is preferably called coronavirus. Formally, it is known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or 2019 novel coronavirus (2019-nCoV) and this disease is called coronavirus disease 2019 (COVID-19). SARS-CoV-2 is infectious in humans and the world health organization has announced COVID-19 as pandemic disease. Tocilizumab is a biological agent that inhibits the cytokine, interleukin 6 (IL-6 inhibitor). As SARS-CoV-2 infection leads to the development of cytokine storm syndrome, the drug, tocilizumab, seems to have a positive effect on patients with COVID-19.
    Aim: To analyze and review the possible effects and efficacy of the tocilizumab (monoclonal antibody against IL-6 receptors) in SARS-CoV-2 patients.
    Materials and methods: A search was carried out for all recent review articles, which were used to study the SARS-CoV-2 disease and their characteristics. Furthermore, we have analyzed the most recent research articles on monoclonal antibody against IL-6 receptors (tocilizumab) and their possible clinical effects in COVID-19 and its' clinical trials.
    Results: COVID-19 is a disease caused by SARS-CoV-2 infection. It is a life threatening condition, which can give rise to fatal outcomes if left untreated. However, there are no approved treatments for COVID-19 globally. Furthermore, we can conclude that SARS-CoV-2 is associated with the worsening of lung conditions, characterized by interstitial pneumonia with acute respiratory distress syndrome as a result of cytokine storm syndrome. According to available research data, tocilizumab, a recombinant humanized anti-human monoclonal antibody of IgG1τ (gamma 1, kappa), can improve patient's condition from cytokine storm syndrome by inhibiting the IL-6 (Interleukin 6) receptors.
    Conclusion: The rational use of the tocilizumab in severe and critically ill COVID-19 patients can prevent the development of irreversible lung injury and death of the patient. Three retrospective studies of Xiaoling Xu et al., Pan luo et al., and Paola Tonaiti et al. have shown the efficacy of tocilizumab in severe and critically ill COVID-19 patients. However, we need more randomized research studies with a significant number of patients which can confirm the promising results on tocilizumab treatment in COVID-19 patients. Moreover, ongoing clinical trails such as TOSCA, COVACTA results have not been published yet which are expected to give better and more significant results on tocilizumab's effectiveness and safety.
    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; COVID-19/complications ; Clinical Trials as Topic ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/etiology ; Humans ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal, Humanized ; tocilizumab (I031V2H011)
    Keywords covid19
    Language English
    Publishing date 2020-10-15
    Publishing country United Arab Emirates
    Document type Journal Article ; Review
    ZDB-ID 2251879-4
    ISSN 1876-1038 ; 1574-8871
    ISSN (online) 1876-1038
    ISSN 1574-8871
    DOI 10.2174/1574887115666200917110954
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6436: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Influence of Inosine on Cerebral Hemodynamics in Space Motion Sickness in Experimental Animals.

    Useinova, Asie N / Kaliberdenko, Vitalii B / Sapegin, Igor D / Kulanthaivel, Shanmugaraj / Shterenshis, Michael V / Dmitriyevskaya, Maria I / Balasundaram, Keerthanaa

    Central nervous system agents in medicinal chemistry

    2021  Volume 21, Issue 2, Page(s) 93–103

    Abstract: Background: Motion sickness occurs worldwide in healthy individuals regardless of age, ethnicity, or gender. It is an acute disorder; it can also present as a chronic disorder in some individuals. Motion sickness not only includes vomiting and nausea, ... ...

    Abstract Background: Motion sickness occurs worldwide in healthy individuals regardless of age, ethnicity, or gender. It is an acute disorder; it can also present as a chronic disorder in some individuals. Motion sickness not only includes vomiting and nausea, but also includes other features such as pallor of varying degrees, cold sweating, headache, drowsiness, increased salivation, and cranial pain, which are severe. Some of the other assessment scales can interpret sickness on exposure to virtual or visual stimulation and while travelling in different types of transport.
    Aim: The aim of our research is to study the effect of the drug on the level of blood flow and vascular reactivity of cerebral vessels when simulating changes in the cerebral circulation in terrestrial conditions characteristic of hypogravity.
    Methods: Chronic experiments were performed on non-anesthetized rabbits with large hemispheres, thalamus and hypothalamus were implanted with the needle-platinum electrodes 150 mm in diameter in the cortex, and local blood flow and vascular reactivity were recorded accordingly. Cerebrovascular disturbances were modeled using an MSAOP (motion sickness of animals in the anti-orthostatic position) with an inclined angle of 45° for 2 hours. Local blood flow (BF) was measured in ml/min/100g of tissue by the method of registration of hydrogen clearance. The vasodilator coefficient of reactivity (CrCO
    Results: Inosine has pronounced protective properties in cerebrovascular disorders on the background of space motion sickness (SMS) modeling, which is manifested by normalization of BF and restoration of compensatory reactions of cerebral vessels. In the mechanism of cerebroprotective action of inosine, it is able to correct the metabolic processes, which play an important role and help increase the compensatory capabilities and functional stability of the cerebrovascular system under gravitational influences.
    Conclusion: When using inosine orally, the effects are more pronounced than when administered intravenously, which should be taken into account when using it for the prevention of cerebrovascular disorders in extreme conditions.
    MeSH term(s) Animals ; Cerebrovascular Circulation ; Hemodynamics ; Inosine ; Motion Sickness/drug therapy ; Rabbits ; Space Motion Sickness
    Chemical Substances Inosine (5A614L51CT)
    Language English
    Publishing date 2021-04-29
    Publishing country United Arab Emirates
    Document type Journal Article
    ZDB-ID 2227560-5
    ISSN 1875-6166 ; 1871-5249
    ISSN (online) 1875-6166
    ISSN 1871-5249
    DOI 10.2174/1871524921666210428111827
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5594: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Tocilizumab in Sars-cov-2 Patients with the Syndrome of Cytokine Storm; a Narrative review

    Kulanthaivel, Shanmugaraj / Kaliberdenko, Vitalii B / Balasundaram, Keerthanaa / Shterenshis, Michael V / Scarpellini, Emidio / Abenavoli, Ludovico

    Reviews on recent clinical trials (Online)

    Abstract: INTRODUCTION: Coronavirus is a group of viruses which causes diseases in mammals and birds. In humans, these family of viruses can cause the respiratory infections from mild form to fatal forms. It is preferably called as coronavirus. Formally it known ... ...

    Abstract INTRODUCTION: Coronavirus is a group of viruses which causes diseases in mammals and birds. In humans, these family of viruses can cause the respiratory infections from mild form to fatal forms. It is preferably called as coronavirus. Formally it known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or 2019 novel coronavirus (2019- nCoV) and this disease is called as coronavirus disease 2019 (COVID-19). SARS-CoV-2 is infectious in humans and world health organization has announced that Covid-19 as a pandemic disease. Tocilizumab is a biological agent which inhibits the cytokine, interleukin 6 (IL-6 inhibitor). As SARS-CoV-2 infection leads to the development of cytokine storm syndrome, the drug tocilizumab seems to have positive effect in patients with covid-19. PURPOSE OF THE STUDY: To analyze and review the possible effects and efficacy of the tocilizumab (monoclonal antibody against IL-6 receptors) in SARS-CoV-2 patients. MATERIALS AND METHODS: The search strategy on recent research and review articles is used for the SARS-CoV-2 disease and their characteristics. Furthermore we have analyzed most recent research article on monoclonal antibody against IL-6 receptors (tocilizumab) and their possible clinical effects in Covid-19 and their clinical trials on Covid-19 patients. RESULTS AND CONCLUSION: Covid-19 is a disease caused by SARS-CoV-2 infection. It is a life threatening condition which can give rise to fatal outcomes if left untreated. However there are no approved treatment for covid-19 globally. Furthermore we can conclude that SARS-CoV-2 is associated with worsening of lung conditions characterized by interstitial pneumonia with acute respiratory distress syndrome as a result of cytokine storm syndrome. According to available research data tocilizumab, a recombinant humanized anti-human monoclonal antibody of IgG1τ (gamma 1, kappa) can improve patient's condition from cytokine storm syndrome by inhibiting the IL-6 (Interleukin 6) receptors. The rational use of the tocilizumab in severe and critically ill covid-19 patients can prevent the development of irreversible lung injury and death of the patient. Three retrospective studies of Xiaoling Xu et al., Pan luo et al. and Paola Tonaiti et al. has shown the efficacy of tocilizumab in severe and critically ill covid-19 patients. However we need more randomized research studies with significant number of patients which can confirm the promising results on tocilizumab treatment in covid-19 patients and even ongoing clinical trails such as TOSCA, COVACTA results has not been published yet which are expected to give better and more significant results on tocilizumab's effectiveness and safety.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #771653
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Tocilizumab in Sars-cov-2 Patients with the Syndrome of Cytokine Storm; a Narrative review

    Kulanthaivel, Shanmugaraj / Kaliberdenko, Vitalii B. / Balasundaram, Keerthanaa / Shterenshis, Michael V. / Scarpellini, Emidio / Abenavoli, Ludovico

    Reviews on Recent Clinical Trials

    2020  Volume 15

    Abstract: Introduction: Coronavirus is a group of viruses which causes diseases in mammals and birds. In humans, these family of viruses can cause the respiratory infections from mild form to fatal forms. It is preferably called as coronavirus. Formally it known ... ...

    Abstract Introduction: Coronavirus is a group of viruses which causes diseases in mammals and birds. In humans, these family of viruses can cause the respiratory infections from mild form to fatal forms. It is preferably called as coronavirus. Formally it known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or 2019 novel coronavirus (2019- nCoV) and this disease is called as coronavirus disease 2019 (COVID-19). SARS-CoV-2 is infectious in humans and world health organization has announced that Covid-19 as a pandemic disease. Tocilizumab is a biological agent which inhibits the cytokine, interleukin 6 (IL-6 inhibitor). As SARS-CoV-2 infection leads to the development of cytokine storm syndrome, the drug tocilizumab seems to have positive effect in patients with covid-19. Purpose of the Study: To analyze and review the possible effects and efficacy of the tocilizumab (monoclonal antibody against IL-6 receptors) in SARS-CoV-2 patients. Materials and methods: The search strategy on recent research and review articles is used for the SARS-CoV-2 disease and their characteristics. Furthermore we have analyzed most recent research article on monoclonal antibody against IL-6 receptors (tocilizumab) and their possible clinical effects in Covid-19 and their clinical trials on Covid-19 patients. Results and Conclusion: Covid-19 is a disease caused by SARS-CoV-2 infection. It is a life threatening condition which can give rise to fatal outcomes if left untreated. However there are no approved treatment for covid-19 globally. Furthermore we can conclude that SARS-CoV-2 is associated with worsening of lung conditions characterized by interstitial pneumonia with acute respiratory distress syndrome as a result of cytokine storm syndrome. According to available research data tocilizumab, a recombinant humanized anti-human monoclonal antibody of IgG1τ (gamma 1, kappa) can improve patient’s condition from cytokine storm syndrome by inhibiting the IL-6 (Interleukin 6) receptors. The rational use of the tocilizumab in severe and critically ill covid-19 patients can prevent the development of irreversible lung injury and death of the patient. Three retrospective studies of Xiaoling Xu et al., Pan luo et al. and Paola Tonaiti et al. has shown the efficacy of tocilizumab in severe and critically ill covid-19 patients. However we need more randomized research studies with significant number of patients which can confirm the promising results on tocilizumab treatment in covid-19 patients and even ongoing clinical trails such as TOSCA, COVACTA results has not been published yet which are expected to give better and more significant results on tocilizumab’s effectiveness and safety.
    Keywords Pharmacology ; General Medicine ; covid19
    Language English
    Publisher Bentham Science Publishers Ltd.
    Publishing country nl
    Document type Article ; Online
    ZDB-ID 2251879-4
    ISSN 1876-1038 ; 1574-8871
    ISSN (online) 1876-1038
    ISSN 1574-8871
    DOI 10.2174/1574887115666200917110954
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6436: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top